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1. Introduction 
Surgical treatment alone for locally advanced rectal cancer (T3/T4 or N1 tumors) has been 
associated with considerably high local recurrence rates. Even with appropriate total 
mesorectal excision (TME), radical surgery leads to excellent local disease control only in 
highly selected cases.(Simunovic et al. 2003) In this setting, the need for additional or 
complementary treatment strategies was highly warranted.  
In the late 80’s and early 90’s it was observed that the addition of adjuvant radiotherapy 
with or without chemotherapy significantly improved disease control as well as survival 
rates in this group of patients.(Krook et al. 1991)  
Later on, results from randomized controlled trials suggested that the neoadjuvant approach 
was superior for local disease control, even when appropriate surgical technique (total 
mesorectal excision) was performed when compared to adjuvant treatment. (Sauer et al. 
2004) Apart from the theoretical advantage of exposing unscarred tissue with optimal 
oxygen delivery to chemoradiation (CRT), further benefits including reduced toxicity rates, 
significant tumor downstaging and downsizing, greater rates of sphincter preservation, and 
better functional results have been reported after neoadjuvant CRT. (Habr-Gama et al. 2004; 
Sauer et al. 2004) 
Tumor downstaging in some patients may be so significant, that no residual cancer was 
detected during final pathological assessment. Still, radical surgery was associated with 
considerably immediate postoperative mortality and morbidity rates. In addition to usual 
postoperative complications, total mesorectal excision may lead to significant sexual and 
urinary dysfunctions. Also, even when abdominal perineal excision (and a permanent 
stoma) could be avoided, temporary loop ileostomies are mandatory in order to avoid 
potential septic consequences of anastomotic leaks in these patients. (Peter Matthiessen et al. 
2007) 
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Therefore, in the setting of a complete tumor regression after neoadjuvant CRT, surgeons 
have searched for alternative management of patients in order to avoid the potential 
consequences of TME with or without abdominal perineal resection. 
2. Factors associated with tumor response after CRT 
Tumor response to neoadjuvant chemoradiation is not uniform and seems to be related to 
many factors such as specific treatment regimen, timing after CRT completion, 
tumor/patient characteristics and tumor biology. 
2.1 Chemoradiation regimen 
Fractionated long course chemoradiation followed by surgery after 6-8 weeks or pelvic 
short-course irradiation with 25Gy in five fractions followed by immediate surgery (short-
course) have been the two most frequent regimens used in the preoperative treatment of 
patients with resectable T3-4 rectal cancer. 
Even though the benefits in local disease control seem to be equivalent between short-course 
RT and long-course chemoradiation therapy,(Bujko et al. 2006) there are significant 
differences in terms of tumor downstaging between patients undergoing these two 
regimens. In patients undergoing short-course RT, the rates of pCR are significantly lower 
when compared with patients undergoing long-course neoadjuvant chemoradiation. Two 
aspects should be considered; first, the long-course regimen includes chemotherapy, second, 
cancer cells damaged after radiotherapy need time to undergo necrosis and usually in 
patients undergoing short-course RT, surgery is performed within 1 week after RT 
completion whereas long-course CRT is followed by radical surgery after at least 6–8 weeks. 
The addition of chemotherapy to radiation in the neoadjuvant setting has resulted not only 
in improvements in local disease control (ie, lower recurrence rates) but also in tumor 
downstaging.(Jose G Guillem et al. 2008) In a randomized trial of patients undergoing RT 
with or without 5-FU– based chemotherapy, patients in the CRT group more frequently had 
a complete pathologic responses less lymph node metastases as well as vascular invasion. 
Additionally, patients treated by CRT had fewer overall lymph nodes recovered in the 
resected specimens and decreased tumor size. (Bosset 2005) 
A review of phase II and III studies using different neoadjuvant CRT regimens for rectal 
cancer identified several predictive factors for complete pathologic response, including the 
dose of radiation therapy delivered, the method of 5-FU infusion, and the use of additional 
drugs to standard 5-FU based regimens. After reviewing 71 studies with over 4,000 patients 
treated with different regimens, complete pathologic response ranged from 0% to 42% and 
was significantly associated with the delivery of radiation doses higher than 45-Gy, 5-FU 
regimens with continous infusion, and the use of a second drug, most frequently oxaliplatin. 
(Sanghera et al. 2008) 
Despite the suggestion that the use of additional drugs (other than 5-FU) could enhance 
tumor response to CRT, recently reported results from a prospective randomized trial 
showed that the addition of oxaliplatin to a 5-FU– based CRT regimen was not associated 
with significantly higher rates of pCR. In turn, patients treated with oxaliplatin experienced 
significantly more treatment-related toxicities. (Gérard et al. 2010) 
Also, the observation of significant activity of targeted biological drugs, such as 
bevazicumab and cetuximab, led to its utilization in phase I and phase II trials in the 
neoadjuvant setting. However, the expected increase in pCR rates among patients 
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undergoing this ‘triple’ therapy (5-FU, oxaliplatin, and cetuximab) was not observed in any 
of the trials. A review of these trials also suggested a subadditive interaction between 
capecitabine, oxaliplatin, and cetuximab as reflected by decreased rates of pCR (9 vs. 16%) 
and significant decrease in tumor regression grades (more than 50% of tumor regression) 
among surgical specimens from these patients when compared with patients undergoing 
treatment with capecitabine and oxaliplatin alone.(Weiss et al. 2010) It is not clear whether 
the inclusion of patients according to the K-ras status could have any influence in response 
to neoadjuvant CRT with this triple approach.(Glynne-Jones et al 2010)  
Considering that 5FU is actually relevant for the development of complete tumor regression 
and that other drugs have been unsuccessful in improving rates without increasing toxicity, 
the use of additional cycles of 5FU in the neoadjuvant regimen has also been suggested. 
With the use of additional cycles of 5FU and leucovorin delivered during RT and during the 
interval period between CRT and tumor response assessment (also known previously as the 
“resting period”), increased rates of complete tumor regression without increased toxicity 
has been reported. (Habr-Gama et al. 2009) 
2.2 Timing of assessment of tumor response 
Assessment of response after CRT is crucial, and remains a real challenge even for the most 
experienced colorectal surgeon. The issues of when and how tumor response assessment 
should be performed are still under debate.  
Since publication of the Lyon Trial in 1999, optimal surgical timing after neoadjuvant CRT 
has been accepted to be 6 weeks. In this study 201 patients with distal rectal cancer T2-3Nx 
were randomized before radiotherapy (39 Gy in 13 fractions) into two groups. The short 
interval group had surgery performed within 2 weeks after completion of radiation therapy 
compared to 6 weeks in the long interval group. After a median follow-up of 33 months, no 
differences in local relapse, morbidity and short-term survival between the two groups 
could be observed. On the other hand, improved clinical tumor responses (p= .007) and 
pathologic downstaging (10.3% v 26% P = .005) were observed in the long interval 
group.(Francois et al. 1999) These results provided the only prospective evidence to support 
a interval period of at least 6 weeks from CRT completion before surgery was performed in 
order to obtain maximal or optimal tumor downstaging. 
Even though there was a suggestion from clinical practice that 8 weeks could probably 
improve the effects of CRT on tumor downstaging, only recent retrospective studies were 
able to provide further support that longer periods after CRT completion could be 
associated with higher rates of tumor downstaging. These studies have shown that patients 
managed by radical surgery 7 to 8 weeks after CRT completion had increased rates of 
complete pathological responses.(Moore et al. 2004; Tulchinsky et al. 2008;) In another 
retrospective review of patients managed by neoadjuvant CRT, a steep increase in complete 
pathological response rates was observed when surgery was performed 7 weeks after CRT 
completion. Even more interesting, these rates of complete response seem to stabilize after 
12 weeks, perhaps suggesting no additional benefit in terms of tumor downstaging after this 
period. (Kalady et al. 2009) Recently, a study compared patients with rectal cancer 
undergoing neoadjuvant CRT followed by radical surgery after 8 or 12 weeks from CRT. 
Even though this study was not randomized and the longer interval group (12 weeks) had 
significantly more advanced disease at baseline, there was a higher rate of pCR rate in this 
latter but without statistical significance. Noteworthy, the authors showed no increase in 
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postoperative surgical complications among the longer interval group (12 weeks). (Garcia-
Aguilar et al. 2011)  
On the other hand, the risk of leaving the tumor in situ for prolonged periods of time, with 
potential metastatic dissemination of tumor cells during this period has been used as an 
argument for performing surgery shortly (<8 weeks) after CRT completion. However, tumor 
cell death seems to be related to a process induced by ionizing radiation. It is thought that 
after exposure to a dose of 44 Gy, metastatic potential of these tumors might decrease 
significantly because of the potential decrease in the overall number of surviving tumor 
cells.(Withers and Haustermans 2004) In recent studies it was found that prolonged 
intervals (>8 weeks) from CRT to surgery may not have any associated oncologic 
compromise. In addition, these patients were associated to less postoperative morbidity, 
further supporting the safety of assessing tumor response at prolonged intervals.(Kerr, 
Norton, and R Glynne-Jones 2008)(Habr-Gama et al. 2008a) 
2.3 Tumor features and biology 
Several aspects of the primary rectal cancer have been considered to be predictors of tumor 
response or complete pathological response to neoadjuvant CRT such as initial disease 
staging, tumor height and extension. Even though very few studies have included patients 
with cT2N0 rectal treated by neoadjuvant CRT, so far there has been no data to support that 
these tumors would develop pCR more frequently. Still, as experience increases with these 
earlier tumors being treated with CRT, there is still a chance that baseline stage is indeed a 
predictor of response to CRT.  
On the other hand, tumor extension has been shown in one retrospective study of over 500 
patients to be a independent predictor of pCR after neoadjuvant CRT. In one study, 
circumferential tumor extent of <60% was a significant predictor of pCR. Even though 
tumor distance from the anal verge was not a predictor of pCR, tumors located in the distal 
5cm of the rectum were more likely to develop greater tumor downstaging.(Das et al. 2007)  
Finally, there is still hope that molecular biology will provide additional information 
regarding tumor response to neoadjuvant CRT. Few studies have addressed the role of gene 
expression in predicting response to CRT. (Ghadimi et al. 2005; I.-J. Kim et al. 2007; Rimkus 
et al. 2008) However, these studies did not seem to agree on what a “good response” was 
and while some of them considered only patients with pCR, others grouped together 
patients with significantly different ypTNM stage classification as long as less than 10% of 
tumor cells were present (based on tumor regression grading systems). The end-result is 
that all three studies suggested a set of genes capable of predicting a “good response” 
without a single gene in common between them.(Perez 2011) In this setting, perhaps further 
studies using more advanced technologies in gene expression analysis may provide more 
definitive and useful information. 
3. Rationale for pursuing a non-operative approach 
Radical surgery (with total mesorectal excision) is still considered fundamental in the 
treatment of distal rectal cancer, considered by many necessary regardless of tumor 
response to neoadjuvant CRT. However, it is associated with significant immediate 
morbidity and mortality. Anastomotic leak is probably the most important complication and 
is reported in up to 12% of cases.(Sauer et al. 2004; Chessin et al. 2005) Perioperative 
mortality may reach 3% and is significantly higher, reaching up to 13% when an 
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anastomotic leak is present among patients who do not undergo temporary diversion.(P 
Matthiessen et al. 2004; Eriksen et al. 2005) Considering the fact that temporary stoma is 
almost always required, additional morbidity or even mortality related to stoma creation 
and take-down should be considered in the cumulative morbidity of rectal cancer 
management. (Perez et al. 2006). Also, even though nerve-preserving technique is now 
standard, the rates of urinary and sexual dysfunctions are quite significant. Finally, even 
though sphincteric function and quality of life among patients undergoing ultra-low 
anterior resections are acceptable, results are far from perfect (Denost et al 2011). Therefore, 
alternative treatment strategies to TME are warranted. 
Considering that final disease stage (after CRT) is the most significant prognostic factor in 
patients with rectal cancer and that pCR is associated with improved oncological outcomes, 
these patients would be ideal candidates for alternative procedures avoiding TME. 
Unfortunately, confirmation of absence of residual microscopic disease is only possible after 
TME.  
After all, is it justified to make our patients undergo a morbid and sometimes mutilating 
procedure when not even a single cancer cell is collected? In this setting, identification of 
patients with complete tumor regression determined by clinical, endoscopic and 
radiological assessment has been proposed in order to avoid immediate TME in a significant 
proportion of cases. Rather than providing a radical shift in the management of rectal 
cancer, this approach suggests close surveillance of a select group of patients with a high 
suspicion of complete tumor response without immediate radical surgery. Therefore, 
patients with no residual cancer may have a chance to be spared from a major surgical 
procedure while patients with residual disease and suspected for complete response may 
have surgery postponed or delayed without oncological compromise 
4. Assessment of tumor response 
Once an alternative approach to patients with rectal based on response to CRT is 
considered, the next step is to establish an efficient and accurate assessment of tumor 
response. Even though there is no perfect tool for such purpose, combination of different 
modalities may provide sufficient information for identification of appropriate candidates to 
non-immediate surgical resection. Patients with no evidence of residual disease by such 
assessment are considered as complete clinical responders (cCR’s). Considering timing is 
crucial for tumor regression after CRT as discussed earlier, assessment of tumor response 
should be performed at least after 8 weeks from CRT and perhaps in some patients after 12 
weeks from CRT. 
4.1 Clinical assessment 
Although clinical symptoms do subside in patients with complete clinical response, a 
significant proportion of patients also present with some degree of symptoms relief despite 
the presence of residual cancer. Therefore, the absence of clinical symptoms should not be 
considered as an absolute marker of complete response to CRT. 
On the other hand, clinical assessment using digital rectal examination and (rigid or 
flexible) proctoscopy are the mainstay of clinical response assessment after CRT. Accuracy 
of clinical assessment of patients with rectal cancer after neoadjuvant CRT has been 
studied with disappointing results regarding sensitivity and specificity by others. Still, 
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these studies were performed using 6-week intervals between CRT completion and 
response assessment and therefore could have detected residual disease in patients with 
ongoing tumor regression. In addition, the inclusion of different examiners could have 
biased results. (Hiotis et al. 2002) 
4.2 Radiological studies  
The use of radiological studies during assessment of tumor response in patients with rectal 
cancer after CRT completion is still a matter of controversy. Staging of primary tumor depth 
of penetration and distance from the circumferential margin seems to be adequately 
provided by endorectal ultrasound and magnetic resonance imaging.  
However, after neoadjuvant CRT, distinguishing between residual cancer and transmural 
fibrosis may be significantly compromised by both imaging methods because these tools 
basically rely on morphologic features.(Mezzi et al. 2009; Suppiah et al. 2009)  
For this reason CT, and endorectal ultrasound (ERUS) are probably best suited for the 
diagnosis of any residual extrarectal disease, such as a mesorectal enlarged nodes or masses. 
Thickening of the rectal wall, densification of the perirectal fat, or the presence of small 
perirectal nodes (less than 5 mm) should not precipitate any specific or immediate surgical 
attention, particular if other studies such as endoscopic and clinical assessment are normal. 
These findings are commonly seen in patients with cCR. 
Previous studies addressed the value of rectal tumor volumetry on standard T2-weighted 
MR images for the assessment of response after CRT but showed conflicting results. One 
report did not find difference in tumor volume reduction rates between patients with pCR 
and those with residual disease.(Y.H. Kim et al. 2005) On the other hand a more recent 
report found a significant association with pCR for patients with a tumor volume reduction 
rate of more than 75%. (Kang et al. 2010)  
With the introduction of diffusion-weighted (DW) MRI, significant amount of interest has 
been focused on this particular study. In a recent multicentric study, three trained 
radiologist reviewed 120 patients, comparing standard MRI with DW MRI and all them 
found improvement in sensitivity and specificity rates using DW MRI.(Lambregts et al. 
2011) Another recent report showed that post-CRT volumetry on DW-MR images were 
significantly more accurate than on T2-weighted MR images to assess a CR after CRT. 
(Curvo-Semedo et al. 2011) Still further studies are needed before these tools are definitively 
incorporated into clinical practice. 
The incorporation of positron emission tomography (PET/CT) imaging into the staging 
work-up provided significant additional information by overlaying metabolic activity data 
to standard radiological morphology. Also, PET imaging may provide an objective estimate 
of the metabolic activity of a specific area as represented by the standard uptake value 
measured at various phases of the study.  
One study of 25 patients with rectal cancer compared the results of baseline PET-CT with a 
second PET-CT performed after 6 weeks from CRT completion. All patients included in the 
study experienced a decrease in maximum standard uptake values (SUVmax) between 
baseline and 6-week PET-CT scans. Also, the final SUVmax obtained at 6 weeks was 
significantly associated with primary tumor downstaging (patients with tumor downstaging 
exhibited significantly lower SUVmax). (Calvo et al. 2004) In another study including 15 
patients undergoing baseline PET followed by a second PET 6 weeks after CRT completion, 
the visual response score was shown to provide superior prediction of tumor downstaging 
in addition of the extent of pathologic response to CRT compared to standard CT.(Guillem 
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et al. 2000) This same group of patients was prospectively followed and outcome analysis 
showed that patients with greater percentual decrease between baseline and 6-week PET 
SUVmax values were associated with improved survival. A cutoff of a 62.5% 
decrease/difference between baseline and 6-week PET SUVmax values was a significant 
predictor of disease-free survival.(Guillem et al. 2004)  
However, these results should be considered carefully, since they included only a small 
number of patients and none of them considered that increased interval periods between 
CRT and tumor response assessment might have influenced results. 
In another study, 30 patients with locally advanced rectal cancer treated with CRT and 
surgery were assessed by pre and post-CRT PET-CT for tumor response after 7 weeks from 
CRT. PET/CT correctly identified six of eight patients (specificity 75 percent) with complete 
pathologic response. However, the sensitivity and accuracy of positron emission 
tomography/computer tomography was only 45 percent and 53 percent respectively. The 
positive and negative predictive values were 83 and 33 percent, respectively. Authors 
concluded that PET/CT performed was not able to predict the pathological response in 
locally advanced rectal cancer. (Kristiansen et al. 2008)  
A prospective study with the use of PET/CT for the assessment of tumor response to CRT is 
currently underway in our Institution analyzing nearly 100 patients with cT2-3NxM0 after 
neoadjuvant CRT. The results of this study may provide significant additional information 
to the role of PET/CT in the assessment of tumor response. 
4.3 Endoscopic biopsies after CRT 
Surgeons and endoscopists are frequently faced with the issue of performing post-CRT 
biopsies in residual lesions within the rectal wall after neoadjuvant CRT. Even though it 
may sound obvious that a positive biopsy may accurately identify incomplete responses, it 
could also be suggested that negative biopsies could possibly help in identifying complete 
pathological responses despite the presence of clinically detectable disease. In fact, there is 
not much evidence regarding the utility of forceps’ biopsies for tumor response assessment. 
In one retrospective review of patients undergoing post-CRT biopsies, the negative 
predictive value was as low as 36%.(Meterissian et al. 1994) However, it must be noted that 
these were unselected patients being assessed significantly earlier than 8 weeks from CRT 
completion. 
In a retrospective review of patients undergoing neoadjuvant CRT restricted to patients with 
significant tumor downsizing, and therefore who were most likely to have developed pCR, 
post-CRT biopsies resulted in a negative predictive value of 21%.(Perez et al. 2011) In this 
setting, a negative biopsy of a clinically detectable lesion, even after significant tumor 
downsizing is not capable of ruling out residual disease and should not prevent surgeons 
from performing radical surgery. Alternatively, select cases may be appropriate for a 
excisional biopsy (through a full-thickness local excision) either as a diagnostic or 
therapeutic procedure. 
4.4 Is there a role for CEA? 
In addition to clinical, radiological and endoscopic assessment of tumor response, 
determination of CEA levels before and after CRT may also be useful. In a study with more 
than 500 patients with rectal cancer managed by neoadjuvant CRT, low CEA before 
treatment was a predictor of ypCR after radical surgery in univariate analysis. (Das et. al. 
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2007) Similar findings have been reported in a retrospective analysis of patients undergoing 
variable neoadjuvant CRT regimens for very low (<2.5 ng/dL) pretreatment CEA levels. 
(Moreno García et al. 2009) 
An increase in CEA levels or persistence of at least 70% from baseline levels has also been 
suggested as a significant predictor of worse outcome patients with CEA levels >6 ng/ml at 
baseline.(C.W. Kim et al. 2011) Also, different cutoff values have been considered for 
patients undergoing CRT when compared to standard colorectal cancer patients. A 
retrospective analysis of 109 patients undergoing neoadjuvant therapy, identified a cutoff 
value for CEA<2.7ng/ml at 4 weeks from RT completion to be a statistically significant 
marker of tumor regression. (Jang et al. 2011)  
The author's own experience with pre and post-CRT CEA levels suggests that only post-
CRT CEA after at least 8 weeks from CRT completion was associated with the development 
of complete clinical response and improved disease-free survival. Both pre-treatment CEA 
and variation between pre and post treatment CEA levels were unpredictable of response 
and oncological outcomes. (Perez et al. 2009) 
5. A Main concern: Lymph node assessment 
In patients undergoing neoadjuvant CRT for rectal cancer, there seems to be tumor 
regression within the primary and perirectal nodes. This observation has been suggested by 
the decreased risk for the presence of lymph node metastases among patients undergoing 
neoadjuvant CRT when compared to patients managed by immediate radical surgery.  
The presence of viable lymph node metastases within the mesorectum despite complete 
primary tumor regression is probably one of the most significant concerns regarding the safety 
of a non-immediate operative approach. The risk of residual nodal disease (N1) in patients 
with complete primary tumor regression (ypT0) may vary between 0% and 7%.(Stipa et al. 
2004; Zmora et al. 2004; Perez et al. 2005; Pucciarelli et al. 2005) Again, these rates might reflect 
differences in doses of radiation therapy and timing of surgery after RT completion. 
Noteworthy, the higher rates of ypT0N1 are associated with patients undergoing surgery no 
longer than 6 weeks after CRT completion and could represent lymph node metastases that 
were still in the process of developing radiation-induced cell death. Additionally, the clinical 
relevance of microscopic residual lymph node metastases is still poorly understood. In a 
parallel to colorectal cancer, the presence of lymph node micrometastases has not been 
completely accepted as a clinically relevant finding.(Fleming et al. 2007) Even in the worst-case 
scenario, the risk of residual microscopic lymph node metastases after ypT0 is still less than the 
risk of residual microscopic lymph node metastases in patients with pT1 rectal cancer, which is 
around 12-13%. (Nascimbeni et al. 2002) 
Still, the concept of nodal sterilization secondary to neoadjuvant CRT remains highly 
controversial. The finding of mucin deposits within lymph nodes that have no residual cancer 
cells in patients with rectal cancer who have received neoadjuvant CRT provides indirect 
evidence of such sterilization.(Perez et al. 2008) Recent data suggests that the presence of 
acellullar mucin is present in up to 27% of specimens with ypCR and 19% of them also showed 
acellular mucin within the nodes recovered after radical resection. Surprisingly, this finding 
had no negative influence on the outcomes of these patients, possibly representing evidence of 
tumor sterilization both within the rectum and the lymph nodes.(Smith et al. 2010) 
Interestingly, the effects of RT or CRT may also be observed in the number of recovered nodes 
after radical surgery. Data obtained from the Surveillance, Epidemiology and End Results 
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(SEER) database indicates that patients undergoing neoadjuvant radiation therapy had 
significantly fewer retrieved nodes from the surgical specimen compared to patients 
undergoing surgery alone after a multivariate analysis. The number of retrieved lymph nodes 
was significantly higher in patients with N1 disease. (Baxter et al. 2005) This observation of an 
overall reduction in the number of lymph nodes among patients undergoing neoadjuvant 
therapy seems to be influenced by the time elapsed between radiation completion and surgical 
resection. One study showed that the number of recovered lymph nodes was significantly 
affected by the interval between CRT completion and surgery, but not by total radiation doses 
delivered. Exposure to longer interval periods led to recovery of fewer lymph nodes in 
surgical specimens. Two implications could be deduced from this: first, the critical number of 
lymph nodes required for proper staging of rectal cancer may not be the same for patients 
undergoing neoadjuvant CRT as for patients who go straight to surgery; second, the effects of 
radiation on lymph nodes seem to be time dependent, similarly to what has been observed for 
primary tumor regression. (Sermier et al. 2006) 
Lymph node recovery may be further influenced by technical issues, including the use of fat-
clearing solutions. In this setting, even though fat cleansing solutions were once considered too 
labor-intensive and potentially toxic, this technique may ultimately result in improvement in 
rectal cancer staging in patients undergoing neoadjuvant CRT. (Wang et al. 2009) 
In a retrospective review of patients with incomplete clinical response after neoadjuvant 
CRT managed by radical surgery, outcomes of patients with no recovered nodes in the 
radical surgery specimen were slightly better than those of patients with node-negative 
disease, and significantly better than patients with node-positive disease. These findings 
suggest that patients with the absence of nodes in the resected specimen may represent a 
subset of patients with particularly increased sensitivity to CRT. (Habr-Gama et al. 2008b) 
6. What is a complete clinical response? 
One of the main limitations for the widespread use of this alternative approach without 
immediate surgery is the lack of a definitive or standardized definition of a complete clinical 
response. In this setting, clinical and endoscopic findings have been suggested as clinically 
useful in defining what is a complete clinical response. (Habr-Gama et al. 2010) 
6.1 Clinical and endoscopic findings in cCR 
Considering endoscopic assessment is performed after 8 weeks from CRT completion, a few 
considerations may be relevant to the decision between a complete and incomplete 
response: 
1. Whitening of the mucosa in an area of the rectal wall may be frequently observed in 
patients with cCR. (Fig. 1)  
2. Teleangiectasia (small derogative blood vessels seen on the rectal mucosa at the area 
previously harboring the primary cancer) is also frequently observed in complete 
clinical responders, even in long-term follow-up. 
3. A subtle loss of pliability of the rectal wall harboring the scar; usually observed during 
manual insufflations at proctoscopy with light stiffness of the wall. In the context of no 
additional positive findings of residual cancer, this may also be considered as a feature 
of cCR 
4. Whenever a tumor cannot be felt or seen, patients should be considered as complete 
clinical responders. 
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6.2 Clinical and endoscopic findings of incomplete response 
Some endoscopic findings should be considered to be at great risk for the presence of 
residual cancer. In any of these situations, a surgical action is probably warranted, at least 
for diagnostic purposes. In this setting, a non-surgical approach may be quite worrisome: 
1. Any residual deep ulceration with or without a necrotic center. 
2. Any superficial ulcer, irregularity, even in the presence of only mucosal ulceration. (Fig. 2) 
3. Any palpable nodule, easily defined by digital rectal examination, even in the presence 
of mucosal complete integrity.  
 
 
Fig. 1. Endoscopic finding in a patient with Complete Clinical response.  
7. The watch-and-wait protocol algorithm 
Patients with complete clinical response, either after clinical assessment or after transanal 
local excision (ypT0), are enrolled in a strict follow-up program (Fig. 3). Adherence to the 
program is critical because distinguishing between complete and near-complete responses 
may sometimes be difficult and final decision may only be possible after a few follow-up 
visits. This is why an empirical 12 month probation period has been suggested where only 
patients that sustain a complete clinical response are considered as cCR’s (Habr-Gama et al. 
1998) (Habr-Gama Ann Surg 2004). 
This algorithm includes monthly follow-up visits with digital rectal examination and rigid 
proctoscopy in every visit for the first 3 months and every two to three months during the 
rest of the first year. CEA levels are determined every 2 months. As discussed previously, 
PET-CT is currently being investigated for its usefulness in tumor response assessment in a 
prospective study. Other radiological studies, including pelvic CT scans or magnetic 
resonance imaging, are performed at the time of initial tumor response assessment, and then 
every 6 months if there are no signs of tumor recurrence. Again, the main objective of these 
radiological studies is to rule out any sign of residual extrarectal disease, such as residual 
nodal disease that would require further investigation or even radical resection. 
Patients are fully informed that complete clinical regression of their primary tumor may be 
temporary and disease recurrence or tumor regrowth may occur at any time during follow-
up. In the case of obvious recurrence or tumor regrowth, radical surgery is strongly 
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recommended. Small nodules or scars may develop over time and can be managed by full-
thickness transanal excision (either standard or Transanal Endoscopic Microsurgery), 
primarily as a diagnostic approach. 
 
 
 
 
Fig. 2. Surgical specimens of rectal adenocarcinoma patients with incomplete responses to 
neoadjuvant chemoradiation therapy. 
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After 1 year of sustained, complete clinical response, patients are recommended for follow-
up visits every 3 months, using the same clinical assessment tools used at initial patient 
assessment.  
This treatment strategy evolved since the beginning of our experience in 1991. Our accuracy 
in clinical assessment of tumor response has probably improved significantly with growing 
experience. At the begining, patients were more frequently followed without immediate 
surgery when a near-complete clinical response was considered with the hope that time 
would lead to a complete clinical response. More recently, these patients have been more 
readily assessed using full-thickness local excision as a diagnostic procedure, and according 
to the pathologic report they are then either managed by strict observation or referred to 
immediate radical surgery. Availability of surgical techniques such as Transanal Endoscopic 
Microsurgery has also lowered the trigger for a excisional biopsy (Full Thickness Transanal 
Local Excision) in the presence of questionable residual lesions. 
 
 
Fig. 3. Watch & Wait Algorithm 
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8. The extended chemoradiotherapy regimen 
An interesting strategy to increase the rates of tumor response is the delivery of chemotherapy 
during the waiting or resting period between radiation completion and tumor response 
assessment. Since February 2005, this approach has been adopted at our Institution. 
Radiation therapy consists of 45 Gy of radiation delivered by a three-field approach with 
daily doses of 1.8 Gy on weekdays to the pelvis, followed by a 9-Gy boost to the primary 
tumor and perirectal tissue (54 Gy total). Concomitantly, patients receive three cycles of 
bolus 5FU (450 mg/m2) and a fixed dose of 50 mg of leucovorin for three consecutive days 
every three weeks. After completion of radiation, patients received three additional identical 
cycles of chemotherapy every three weeks (21 days) during nine weeks. Tumor response 
assessment is performed immediately at 10 weeks from radiation completion. (Fig 4) 
In a preliminar report of our series including T2/T3 distal rectal cancers, the sustained 
complete clinical response rate (>12 months) was 65% with no significant increase in 
chemotherapy-related toxicity rates. After a recent update of this same cohort of patients, 
complete clinical response rate seems to be sustained after a median follow-up of more than 
36 months at 65%.(Habr-Gama et al. 2009) 
 
 
Fig. 4. The extended Chemoradiation regimen 
9. Long-term results 
At the beginning of our experience several patients were managed by radical surgery since 
residual cancer could not be confirmed or ruled out. This included patients with residual 
scars that were not candidates for local excision and those with partial narrowing of the 
rectum. In this context, many patients were operated and found to have ypT0 (absence of 
residual tumor). More recently, incorporation of TEM (Transanal Endoscopic Microsurgery) 
for diagnostic or staging purposes may lead to a significant decrease in the rates of pCR 
after radical TME. 
In an attempt to understand the potential benefits of oncological surgery in terms of survival 
and local disease control, we performed a retrospective study where patients with complete 
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pathological response (pCR) were compared to patients with cCR managed non-
operatively.(Habr-Gama et al. 2004) 
Patients managed by observation alone had similar outcomes to those managed by radical 
surgery in terms of long term survival. On the other hand, local recurrences were higher on the 
observation group, but noteworthy, all recurrences were within the rectal wall and amenable 
to surgical salvage. No pelvic relapses without endorectal component was observed. 
Five-year overall and disease-free survival rates were associated to disease stage (clinical or 
pathological) and were 88% and 83%, respectively, in pCR group and 100% and 92% in cCR 
group respectively. These excellent survival rates in patients stage pCR and cCR were 
significantly better than those observed in patients ypII and ypIII. Curiously patients with 
stage ypI had intermediate results (Habr-Gama A, Perez RO, Nadalin W, et al. Long-term 
results of preoperative chemoradiation for distal rectal cancer correlation between final 
stage and survival. J Gastrointest Surg 2005;9:90-9; discussion 9-101.). 
10. Survival and recurrences 
Final TNM classification after neoadjuvant CRT remains the best predictor of survival in 
patients with rectal cancer. In a study of patients with similar baseline stages, final 
pathological classification distinguished those with worse and better outcomes. 
Still, there is no prospective evidence favoring neoadjuvant RT over adjuvant CRT in terms 
of survival benefits. One explanation for this observation could be the detrimental effect of 
neoadjuvant CRT on host immunologic response against rectal cancer such as the potential 
blockade of peritumoral inflammatory as immunologic response.(Perez et al. 2007) 
It has been suggested that adjuvant chemotherapy can improve survival only in highly 
selected patients with substantial tumor downstaging (ypT0-2).(Collette et al. 2007) These 
results may lead to a dramatical change in management of these patients who used to be 
considered for adjuvant treatment according to pretreatment staging.  
An interesting observation is that in our series, systemic recurrences in cCR patients 
occurred considerably earlier than local recurrences. Besides intrinsic tumor behavior, this 
could be partly explained by the staging inaccuracy of the different available imaging 
modalities, which were probably not capable of detecting microscopic foci or metastasic 
disease at initial presentation. Also, local recurrences were observed in 10% of patients 
managed nonoperatively after a cCR. Interestingly, there were no extrarectal pelvic 
recurrences. Even though some recurrences may develop from the outer layers of the rectal 
wall, in all cases there was some luminal evidence of recurrence that could be detected by 
digital and rectoscopic examination. 
Again, local recurrences developed considerably later during follow-up. This has also been 
observed in other series, where more than one third of patients who develop local 
recurrences after neoadjuvant CRT and radical surgery did so after 5 years of follow-up. In 
contrast, 75% of patients who develop local recurrences after radical surgery alone do so 
within 2 years of follow-up. This information may have implications when considering 
follow-up and surveillance strategies.( Habr-Gama et al. 2008a) 
11. Salvage therapy 
It has to be highlighted that up to now, all local recurrences in patients with cCR after 
neoadjuvant CRT were amenable to salvage therapy. These recurrences and their salvage 
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procedures were performed at considerably long intervals after CRT completion (mean >50 
months). In almost half of the cases an abdominoperineal resection (APR) was performed. 
Also, almost one third of these patients presented with low and superficial recurrences, 
amenable to full thickness transanal excision.(Habr-Gama et al. 2006) 
A significant subgroup of patients, presented early tumor regrowth (within 12 months from 
CRT completion). These patients were most commonly misdiagnosed as cCR and had their 
definitive surgical treatment postponed for a variable period of time. This raised the issue 
whether these patients could have been harmed from an oncologic standpoint, by delaying 
definitive surgical resection. However, long-term data revealed that they fared no worse 
than patients with incomplete clinical response and managed by radical surgery after 8 
weeks from CRT completion. Noteworthy, final pathology in this group revealed significant 
tumor downstaging and even lower rates of lymph node metastases, further supporting the 
idea that downstaging is a time-dependent phenomenon. The fact that these patients were 
more frequently managed by APR, could reflect the motivation (by the surgeon and the 
patient) to delay final decision on radical resection, knowing that tumor regression could be 
still going on.(Habr-Gama et al. 2008a) 
12. Perspectives 
Several aspects in the management of complete clinical response after neoadjuvant CRT 
remain unresolved and should be a focus of future clinical and basic science research. 
Novel radiation therapy regimens including alternative radiation doses, delivery methods, 
and technical variants to maximize radiation-related tumor cell death and minimize side 
effects is an area of special interest. In addition, improved chemotherapy regimens might 
lead to an increase in the rate of complete clinical response and, possibly, improve survival 
rates. Some investigators have suggested the use of aggressive induction chemotherapy 
before the delivery of radiation to provide immediate treatment of undetected microscopic 
foci of metastatic tumor cells in addition to the primary tumor. These regimens are currently 
under investigation in controlled trials to provide data on safety and long-term 
benefits.(Chua et al. 2010)  
Another interesting and relevant topic in rectal cancer management is the optimal interval 
between CRT completion and assessment of tumor response, as already said. Ongoing 
prospective randomized trials comparing different intervals may provide additional 
information regarding this particular issue in rectal cancer management. Also, perhaps data 
from PET/CT imaging at different intervals from CRT completion may also indicate kinetics 
of tumor metabolism as function of time in these patients.  
Finally, development of next generation sequencing technology may allow further 
understanding of molecular genetic events relevant to sensitivity or resistance to neoadjuvant 
CRT. Perhaps identification of gene signatures will allow improvement of patient selection 
leading to true individualized management decisions. There is hope that studies using 
RNAseq technology may provide more definitive information in the near future. 
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